{'fraction_non_alphanumeric': 0.024793388429752067, 'fraction_numerical': 0.01652892561983471, 'mean_word_length': 6.126050420168068, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Benefit Coverage of Novel Antipsychotics in Medicaid Programs and the Veterans Health Administration

When risperidone, olanzapine, and quetiapine were introduced, concerns were raised regarding the extent to which drug benefit policies might constrain their use. A national survey of eligible Medicaid programs (N = 47; 100%) and Veterans Health Administration facilities (N = 141; 94%) in 1998 found that within Medicaid, open formularies were common, preauthorization requirements were rare, and few barriers existed, whereas VHA facilities reported relatively more constraints in terms of formulary restrictions and preauthorization requirements. Although drug benefit policies have the potential to exert a major influence over prescribing practices, it is unlikely that these policies significantly restricted access to these antipsychotics.